The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Nanocarriers for delivery of platinum anticancer drugs
Open accessAbstract
Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
(1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242402 · Cited by 2,733
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., & Insalaco, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,658
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Micellization of block copolymers
Riess, G. (2003) · Progress in Polymer Science · doi:10.1016/s0079-6700(03)00015-7 · Cited by 1,953
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00226-0 · Cited by 1,588
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
Esfand, R., & Tomalia, D. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01757-3 · Cited by 1,562
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
Nano-engineering block copolymer aggregates for drug delivery
Allen, C., Maysinger, D., & Eisenberg, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00058-2 · Cited by 1,358
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J. W., Meijer, E. W., Paulus, W., & Duncan, R. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00246-1 · Cited by 1,227
Boas, U., & Heegaard, P. M. H. (2004) · Chemical Society Reviews · doi:10.1039/b309043b · Cited by 1,175
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
Synthesis, Characterization, and Applications of Dendrimer-Encapsulated Nanoparticles
Scott, R. W. J., Wilson, O. M., & Crooks, R. M. (2005) · The Journal of Physical Chemistry B · doi:10.1021/jp0469665 · Cited by 866
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Harada, A., & Kataoka, K. (1995) · Macromolecules · doi:10.1021/ma00119a019 · Cited by 848
The emerging field of nanotube biotechnology
Martin, C. R., & Kohli, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd988 · Cited by 791
Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery
Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00015-7 · Cited by 756
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Protein adsorption to poly(ethylene oxide) surfaces
Gombotz, W. R., Guanghui, W., Horbett, T. A., & Hoffman, A. S. (1991) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820251211 · Cited by 634
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 604
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Knox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., et al. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257742 · Cited by 484
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Yang, S.-T., Wang, X., Jia, G., Gu, Y., Wang, T., Nie, H., Ge, C., Wang, H., & Liu, Y. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.07.020 · Cited by 458
Lieberthal, W., Triaca, V., & Levine, J. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.4.f700 · Cited by 449
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Dendrimer-platinate: a novel approach to cancer chemotherapy.
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · PubMed · Cited by 417
Carbon Nanohorns as Anticancer Drug Carriers
Ajima, K., Yudasaka, M., Murakami, T., Maigné, A., Shiba, K., & Iijima, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500566 · Cited by 411
Kabanov, A. V., Bronich, T. K., Kabanov, V. A., Yu, K., & Eisenberg, A. (1996) · Macromolecules · doi:10.1021/ma960120k · Cited by 408
Self-citationDendrimer-platinate: a novel approach to cancer chemotherapy
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00010 · Cited by 402
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Tumour-inhibiting platinum complexes—state of the art and future perspectives
Jakupec, M. A., Galanski, M. S., & Keppler, B. K. (2003) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/s10254-002-0001-x · Cited by 393
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Clinical Features of Hypersensitivity Reactions to Carboplatin
Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., & Belinson, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1141 · Cited by 365
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Oxaliplatin-safety profile: neurotoxicity
GROTHEY, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00399-3 · Cited by 319
Ishida, O., Maruyama, K., Sasaki, K., & Iwatsuru, M. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00256-2 · Cited by 308
Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects
Kabanov, A. V., & Kabanov, V. A. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00106-3 · Cited by 307
Self-citationCisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells
Lacour, S., Hammann, A., Grazide, S., Lagadic-Gossmann, D., Athias, A., Sergent, O., Laurent, G., Gambert, P., Solary, E., & Dimanche-Boitrel, M.-T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2787 · Cited by 306
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs
Luxenhofer, R., Schulz, A., Roques, C., Li, S., Bronich, T. K., Batrakova, E. V., Jordan, R., & Kabanov, A. V. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.057 · Cited by 286
Self-citationPreclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., & Amantea, M. A. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
Stewart, L. A., Aabo, K., Adnitt, P. I., Adams, M., Alberts, D. S., Barley, V., Bell, D. R., Bianchi, U., Blessing, J. A., Buyse, M. E., et al. (1991) · Cited by 270
Polymer micelle with cross-linked ionic core
Bronich, T. K., Keifer, P. A., Shlyakhtenko, L. S., & Kabanov, A. V. (2005) · Journal of the American Chemical Society · doi:10.1021/ja043042m · Cited by 264
Self-citationPolymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Fichtinger-Schepman, A. M., van Oosterom, A. T., Lohman, P. H. M., & Berends, F. (2026) · PubMed · doi:10.82135/tno-230308 · Cited by 264
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M. R., Yamori, T., Nishiyama, N., & Kataoka, K. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001385 · Cited by 262
Nishiyama, N., Yokoyama, M., Aoyagi, T., Okano, T., Sakurai, Y., & Kataoka, K. (1999) · Langmuir · doi:10.1021/la980572l · Cited by 259
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
Liposomes as ‘smart’ pharmaceutical nanocarriers
Sawant, R. R., & Torchilin, V. P. (2010) · Soft Matter · doi:10.1039/b923535n · Cited by 243
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Tsuruya, K., Ninomiya, T., Tokumoto, M., Hirakawa, M., Masutani, K., Taniguchi, M., Fukuda, K., Kanai, H., Kishihara, K., Hirakata, H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00709.x · Cited by 241
Ajima, K., Murakami, T., Mizoguchi, Y., Tsuchida, K., Ichihashi, T., Iijima, S., & Yudasaka, M. (2008) · ACS Nano · doi:10.1021/nn800395t · Cited by 240
Drug transporters of platinum-based anticancer agents and their clinical significance
Burger, H., Loos, W. J., Eechoute, K., Verweij, J., Mathijssen, R. H. J., & Wiemer, E. A. C. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2010.12.002 · Cited by 230
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Folate-decorated nanogels for targeted therapy of ovarian cancer
Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V., & Bronich, T. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.006 · Cited by 223
Self-citationPlatinum organ toxicity and possible prevention in patients with testicular cancer
Hartmann, J. T., Kollmannsberger, C., Kanz, L., & Bokemeyer, C. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<866::aid-ijc34>3.0.co;2-9 · Cited by 219
Culy, C. R., Clemett, D., & Wiseman, L. R. (2000) · Drugs · doi:10.2165/00003495-200060040-00005 · Cited by 217
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
Lee, S.-M., O’Halloran, T. V., & Nguyen, S. T. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107333g · Cited by 213
Curing metastatic cancer: lessons from testicular germ-cell tumours
Masters, J. R. W., & Köberle, B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1120 · Cited by 208
Sternberg, C. N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P. H. T. J., Vekemans, K., van Erps, P., Theodore, C., Koriakine, O., Oliver, T., et al. (2005) · Oncology · doi:10.1159/000084201 · Cited by 206
Cabral, H., Nishiyama, N., Okazaki, S., Koyama, H., & Kataoka, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.022 · Cited by 201
Coste, F., Malinge, J.-M., Serre, L., Leng, M., Zelwer, C., Shepard, W., & Roth, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.8.1837 · Cited by 199
Polymeric micelles for oral drug delivery: Why and how
Francis, M. F., Cristea, M., & Winnik, F. M. (2004) · Pure and Applied Chemistry · doi:10.1351/pac200476071321 · Cited by 197
Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs
Bontha, S., Kabanov, A. V., & Bronich, T. K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.015 · Cited by 196
Self-citationNanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity
Burger, K. N. J., Staffhorst, R. W. H. M., de Vijlder, H. C., Velinova, M. J., Bomans, P. H., Frederik, P. M., & de Kruijff, B. (2002) · Nature Medicine · doi:10.1038/nm0102-81 · Cited by 189
Nishiyama, N., Kato, Y., Sugiyama, Y., & Kataoka, K. (2001) · Pharmaceutical Research · doi:10.1023/a:1010908916184 · Cited by 186
Bhirde, A. A., Patel, S., Sousa, A. A., Patel, V., Molinolo, A. A., Ji, Y., Leapman, R. D., Gutkind, J. S., & Rusling, J. F. (2010) · Nanomedicine · doi:10.2217/nnm.10.90 · Cited by 177
Anticancer Efficacies of Cisplatin-Releasing pH-Responsive Nanoparticles
Xu, P., Van Kirk, E. A., Murdoch, W. J., Zhan, Y., Isaak, D. D., Radosz, M., & Shen, Y. (2006) · Biomacromolecules · doi:10.1021/bm050902y · Cited by 171
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
Nowotnik, D. P., & Cvitkovic, E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.004 · Cited by 167
Mollman, J. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220210 · Cited by 163
Cabral, H., Nishiyama, N., & Kataoka, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.024 · Cited by 161
Gupta, A. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00508-1 · Cited by 160
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.009 · Cited by 159
Nishiyama, N., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00314-5 · Cited by 153
White, S. C., Lorigan, P. C., Margison, G. P., Margison, J. M., Martin, F., Thatcher, N., Anderson, H., & Ranson, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603345 · Cited by 152
DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464
Kašpárková, J., Zehnulová, J., Farrell, N. P., & Brabec, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208016200 · Cited by 147
Polymer Therapeutics for Cancer: Current Status and Future Challenges
Satchi‐Fainaro, R., Duncan, R., & Barnés, C. M. (2005) · Springer eBooks · doi:10.1007/12_024 · Cited by 146
Dragovich, T., Mendelson, D. S., Kurtin, S. E., Richardson, K., Hoff, D. D. V., & Hoos, A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0235-4 · Cited by 142
Is Cisplatin a Human Carcinogen?
Greene, M. H. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.5.306 · Cited by 142
A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt, G. A., Grygiel, J. J., Corden, B. J., Ozols, R. F., Weiss, R. B., Tell, D. T., Myers, C. E., & Collins, J. M. (1983) · PubMed · Cited by 141
Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma
Kushner, B. H., Budnick, A. S., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Cancer · doi:10.1002/cncr.22004 · Cited by 141
Scheeff, E. D., Briggs, J. M., & Howell, S. B. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.633 · Cited by 137
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim, E. S., Lu, C., Khuri, F. R., Tonda, M. E., Glisson, B. S., Liu, D., Jung, M., Hong, W. K., & Herbst, R. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00278-1 · Cited by 136
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
Chollet, P. J. M., Bensmaïne, M. A., Brienza, S., Deloche, C., Curé, H., Caillet, H., & Cvitkovic, E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010500 · Cited by 134
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
Boulikas, T. (2004) · Oncology Reports · doi:10.3892/or.12.1.3 · Cited by 134
Duncan, R., Ringsdorf, H., & Satchi‐Fainaro, R. (2006) · Journal of drug targeting · doi:10.1080/10611860600833856 · Cited by 132
Li, X., Li, R., Qian, X., Ding, Y., Tu, Y., Guo, R., Hu, Y., Jiang, X., Guo, W., & Li, R. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.016 · Cited by 129
Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V., & Stathopoulos, J. (2005) · Oncology Reports · doi:10.3892/or.13.4.589 · Cited by 128
Liaw, J., Chang, S.-F., & Hsiao, F.-C. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301485 · Cited by 127
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Katano, K., Safaei, R., Samimi, G., Holzer, A. K., Rochdi, M., & Howell, S. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.466 · Cited by 126
Cisplatin-associated neurotoxicity: can it be prevented?
Alberts, D. S., & Noel, J. K. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199506000-00003 · Cited by 126
Han, Y., He, Z., Schulz, A., Bronich, T. K., Jordan, R., Luxenhofer, R., & Kabanov, A. V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300159u · Cited by 125
Self-citationPolymeric drug delivery of platinum-based anticancer agents
Haxton, K. J., & Burt, H. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21611 · Cited by 125
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
Terwogt, J. M. M., Groenewegen, G., Pluim, D., Maliepaard, M., Tibben, M. M., Huisman, A., Huinink, W. W. T. B., Schot, M. E., Welbank, H., Voest, E. E., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100371 · Cited by 124
Rice, J. R., Gerberich, J. L., Nowotnik, D. P., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2169 · Cited by 117
Campone, M., Rademaker-Lakhai, J. M., Bennouna, J., Howell, S. B., Nowotnik, D. P., Beijnen, J. H., & Schellens, J. H. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0397-0 · Cited by 115
Synthesis and Properties of Low Molecular Weight Polyphosphazenes
Sohn, Y. S., Cho, Y. H., Baek, H., & Jung, O. (1995) · Macromolecules · doi:10.1021/ma00126a039 · Cited by 114
Cisplatin and Oxaliplatin Toxicity: Importance of Cochlear Kinetics as a Determinant for Ototoxicity
Hellberg, V., Wallin, I., Eriksson, S., Hernlund, E., Jerremalm, E., Berndtsson, M., Eksborg, S., Arnér, E. S. J., Shoshan, M. C., Ehrsson, H., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn418 · Cited by 113
Broadening the clinical use of platinum drug–based chemotherapy with new analogues
Kèlland, L. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1009 · Cited by 112
Bonetti, A. V., Leone, R., Muggia, F. M., & Howell, S. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-459-3 · Cited by 112
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Self-citationModelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes
Hilder, T. A., & Hill, J. M. (2007) · Nanotechnology · doi:10.1088/0957-4484/18/27/275704 · Cited by 110
Hypersensitivity and idiosyncratic reactions to oxaliplatin
Thomas, R. R., Quinn, M. G., Schüler, B., & Grem, J. L. (2003) · Cancer · doi:10.1002/cncr.11379 · Cited by 110
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Kirkpatrick, G. J., Plumb, J. A., Sutcliffe, O. B., Flint, D. J., & Wheate, N. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.05.017 · Cited by 105
Intestinal uptake and biodistribution of novel polymeric micelles after oral administration
Mathot, F., van Beijsterveldt, L., Véronique Préat, A., Brewster, M. E., & Ariën, A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.012 · Cited by 101
Oberoi, H. S., Laquer, F. C., Marky, L. A., Kabanov, A. V., & Bronich, T. K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.028 · Cited by 95
Self-citationYellepeddi, V., Kumar, A., Maher, D. M., Chauhan, S. C., Vangara, K. K., & Palakurthi, S. (2011) · PubMed · Cited by 93
Cabral, H., Murakami, M., Hojo, H., Terada, Y., Kano, M. R., Chung, U., Nishiyama, N., & Kataoka, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301348110 · Cited by 92
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
von Schlippe, M., Fowler, C. J., & Harland, S. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2006 · Cited by 92
Sood, P., Thurmond, K. B., Jacob, J. E., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600517 · Cited by 91
Duong, H. T. T., Huynh, V. T., SOUZA, P. D., & Stenzel, M. H. (2010) · Biomacromolecules · doi:10.1021/bm100396s · Cited by 91
Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan, P., Tarabishi, R., Mishra, J., Ma, Q., Kourvetaris, A., Vougiouka, M., & Boulikas, T. (2004) · PubMed · Cited by 91
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Sankhala, K. K., Mita, A. C., Adinin, R., Wood, L. M., Beeram, M., Bullock, S., Yamagata, N., Matsuno, K., Fujisawa, T., & Phan, A. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2535 · Cited by 84
Ajima, K., Yudasaka, M., Maignè, A., Miyawaki, J., & Iijima, S. (2006) · The Journal of Physical Chemistry B · doi:10.1021/jp056813x · Cited by 82
Haririan, I. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s8595 · Cited by 81
Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance
Peleg‐Shulman, T., Gibson, D., Cohen, R., Abra, R. M., & Barenholz, Y. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00359-x · Cited by 80
Lu, C. S., Perez-Soler, R., Piperdi, B., Walsh, G. L., Swisher, S. G., Smythe, W. R., Shin, H. J. C., Ro, J. Y., Feng, L., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.802 · Cited by 79
Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs
Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 77
Ye, L., Letchford, K., Heller, M., Liggins, R., Guan, D., Kizhakkedathu, J. N., Brooks, D. E., Jackson, J. K., & Burt, H. M. (2010) · Biomacromolecules · doi:10.1021/bm101080p · Cited by 77
Stathopoulos, G., Boulikas, T., Vougiouka, M., et al. (2006) · Oncology Reports · doi:10.3892/or.15.5.1201 · Cited by 75
Allcock, H. R., Pucher, S. R., & Scopelianos, A. G. (1994) · Macromolecules · doi:10.1021/ma00079a001 · Cited by 73
Rafi, M., Cabral, H., Kano, M. R., Mi, P., Iwata, C., Yashiro, M., Hirakawa, K., Miyazono, K., Nishiyama, N., & Kataoka, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.038 · Cited by 71
Tulub, A. A., & Стефанов, В. Е. (2001) · International Journal of Biological Macromolecules · doi:10.1016/s0141-8130(00)00159-8 · Cited by 71
Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G., Little, M., Yule, S. M., Morland, B. J., Estlin, E., Hale, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1723 · Cited by 69
Gao, H., Yang, Y., Fan, Y., & Ma, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.016 · Cited by 67
Gianasi, E., Buckley, R. G., Latigo, J. R., Wasil, M., & Duncan, R. (2002) · Journal of drug targeting · doi:10.1080/1061186021000072456 · Cited by 64
Long-Term Renal Effect of Cisplatin in Man
Brilleta, G., Demya, G., Jacquiauda, C., et al. (1994) · American Journal of Nephrology · doi:10.1159/000168693 · Cited by 64
Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda, A. C., Goel, R., Berdzik, J., Leichman, C. G., & Javle, M. M. (2004) · PubMed · Cited by 62
Oberoi, H. S., Nukolova, N. V., Laquer, Poluektova, L. Y., Alnouti, Yokohira, Arnold, Kabanov, A. V., Cohen, Bronich, et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29145 · Cited by 60
Self-citationMcDonald, B. R., Kirmani, S., Vasquez, M., & Mehta, R. L. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80022-e · Cited by 59
Kapp, T., Dullin, A., & Gust, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900406m · Cited by 57
Improved targeting of platinum chemotherapeutics
Lin, X., Zhang, Q., Rice, J. R., Stewart, D. R., Nowotnik, D. P., & Howell, S. B. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.09.022 · Cited by 56
Labaye, J., Sarret, D., Duvic, C., Herody, M., Didelot, F., Nedelec, G., & Noël, L. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh826 · Cited by 54
Synthesis, characterization, and tumor selectivity of a polyphosphazene–platinum(II) conjugate
Song, R., Jun, Y. J., Kim, J. I., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.016 · Cited by 52
Rosenthal, D. I., Yom, S. S., Liu, L., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016201732368 · Cited by 51
Koukourakis, M. I., Giatromanolaki, A. N., Pitiakoudis, M., Kouklakis, G., Tsoutsou, P. P., Abatzoglou, I. M., Panteliadou, M., Sismanidou, K., Sivridis, E., & Boulikas, T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1733 · Cited by 50
Perez-Soler, R., Shin, D. M., Siddik, Z. H., Murphy, W. K., Huber, M., Lee, J. S., Khokhar, A. R., & Hong, W. K. (1997) · PubMed · Cited by 49
Farhat, F., Temraz, S. N., Kattan, J. G., Ibrahim, K., Bitar, N., Haddad, N., Jalloul, R., Hatoum, H. A., Nsouli, G., & Shamseddine, A. I. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.08.005 · Cited by 48
Amin, A., & Buratovich, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361566 · Cited by 47
Xue, Y., Tang, X., Huang, J. T., Zhang, X., Yu, J., Zhang, Y., & Gui, S. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.02.040 · Cited by 47
Senzer, N. N., Matsuno, K., Yamagata, N., Fujisawa, T., Wasserman, E., Sutherland, W., Sharma, S., & Phan, A. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-c36 · Cited by 40
Treatment of patients with cisplatin-refractory testicular germ-cell cancer
Bokemeyer, C., Kollmannsberger, C., Harstrick, A., Beyer, J., Gerl, A., Casper, J., Metzner, B., Hartmann, J. T., Clemm, C., Schmoll, H., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.0.co;2-# · Cited by 39
Block ionomer complex micelles with cross-linked cores for drug delivery
Kim, J. O., Nukolova, N. V., Oberoi, H. S., Kabanov, A. V., & Bronich, T. K. (2009) · Polymer Science Series A · doi:10.1134/s0965545x09060169 · Cited by 38
Self-citationA novel micelle-encapsulated platinum(II) anticancer agent
Jadhav, V. B., Jun, Y. J., Song, J. H., Park, M. K., Oh, J. H., Chae, S. W., Kim, I.-S., Choi, S.-J., Lee, H. J., & Sohn, Y. S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.101 · Cited by 36
Scientists and clinicians test their metal–back to the future with platinum compounds
Guminski, A. D., Harnett, P. R., & DeFazio, A. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00733-7 · Cited by 34
Acute renal failure related to oxaliplatin-induced intravascular hemolysis
Ulusakarya, A., Misra, S. C., Haydar, M., Habert, H., Castagné, V., Gumus, Y., Delmas-Marsalet, B., & Machover, D. (2009) · Medical Oncology · doi:10.1007/s12032-009-9263-3 · Cited by 31
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Metadata
- Authors
- Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1667-1685
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2091945030
- Cited by
- 396
- References
- 214
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.